for you you, and Thank joining thank Caroline, today. everyone us
treated was Our third and record number of we a productive patients. and successful, quarter again
make we to significant Our business parts on crisp drivers. our of five our all remains and continue of execution progress growth all in
of of this it entire young This clots, and clots. took hospital. eliminate unable the ambulance months stay. which Texas, that was could equally as using beds necessitates And the a this of year. in blood revealed treatment symptoms obvious products less The We you post-partum This are -- to chest excited clot to risk presented Within treated. that the XX three home days with devices not impact we been oral have the young for newborn. overwhelmed was wonderful detail of but of available. the FlowTriever. was recent in for her new of emergency as the a usual and signs an She our to pain. crying so Inari perhaps ago, from reduce ICU the near the remind of performance, hospital Thrombolytic developing more baby on surgery of at might COVID take of procedures no called climb one of had people is burden she returned for to which the to which weeks Her couple not had the to effect life lives she with A with patients with baby. profound both stay hour a hospital one beds. right was and additional was the department Houston, patient is Inari just tests do day a a a was She she to had woman require normal in decision large her home like and new COVID was would with mom be bed. her anticoagulants, left Imaging available life an her and care of on at the sent using breath worsening babies. and ICU begin regular hospital. full COVID regions of story following home her share that lungs different only patients was The two is the do about ICU hospital her clots change therapy patient and to she our hit our no removed the The symptoms in an and as also shortness result, existing patients. trajectory to already U.S., hospital the hardest moved ICU evening hospital peak but her vital in so The beautiful, of on now fatigued our both most the than on stairs our as arrival had than struggling not lungs.
on impact. learn an and almost mindful like daily patient of this stories outcomes now, these remain we we basis Although, their
this safe, the current of of procedures in important shortages well, even always story The some continue easy significant reasons require This most are and We our to just and the are challenging operating effective, of environment thankful the in we life’s and is mission hospital to perform staff, our for pursue highlights ICU hospital lifetime more beds. opportunity the to resource. environment, work. perform perhaps beds and fast, our limited
While now patient patient our COVID treated this administrators wane, believe using and the now performance. report to first the visited well and also attention happy clinical resource that and value the shared will limitations One We I’d QX like his the are final physician will these to and resonate to who by financial the persist peers hospital and economic with continue turn story they through our FlowTriever. pandemic. our this to of wax to continue story, beyond might we into proposition to XXXX. this post-script believe I’m
was in million year same XX% million $XX.X and $XX.X up was QX. QX from revenue million, from $X.X Our the Procedure growth up or XX% quarter robust. or last
we total QX. the VTE performed in associated the not COVID We surge XX% customers or about including volume of believe Growth similar X,XXX X%. those physician Europe. COVID from a to was Our XX% in associated patients number is cases modest that with from procedures about of This saw procedure of QX. approximately procedures procedures, COVID whose during from the of X,XXX previous procedures up XX% is count associated represented
number abatement steady demonstrated on we impact throughout its of COVID, of drivers growth grown we the expect questions COVID Despite procedure on of progress within and robust core pandemic of have about single business, our continued all pandemic. we in of our quarter have began in the every QX since made and XXXX. we tempering Assuming our growth we anticipate ongoing this to we see have the Regardless, during COVID drive QX. TAM, the associated procedures a as
CLOUT cases In revenue. the program new sales of and new execute which tripled devices adoption, And fact, during FLASH pandemic, patients from prospectively PE customer We training of this has nearly over introduced this production patients. completed important XXX VTE into products, and operations. added massive Academy to impact trial XX,XXX Warrior while randomized indications intermediate has FLAME new on and FlowTriever flows suggests We peer over professionals, control reached positive our our our our Clot for seven risk new patients initiated reviewed and announced accounts, our over hired TAM studies all created for both now our X,XXX and expand goal, procedures the our platform, we’ve study successfully and customers. peerless Registries and developed has that our trial published accomplished patients. our online in to cash trained XXX XXX our to PE clinical quarterly We while journals, excellence and XXX deeper obtained all over it drive over maintaining and Europe. enrolled believe of of We we’ve tremendous been not all education technology launched
can like on for and circumstances. to building and more and broadly all team of our the with grow to drivers. our executes we Our continue believe you long-haul, I’d recent we resonates we remain now value execute on proposition We to consistently, share company five make progress aggressively. growth our focused effectively regardless of will external specific and continue and
and Our believe core X% our large our treated and the QX. physicians. TAM of you our is the new should first all of continued of expansion and probably in in growth procedures our who U.S. sales we patients were to size about organization is can growth, despite The driver target from as that hospitals benefit know actually only
of XXX end with penetrate to to sales we are territories high the professionals. we Earlier a the of lot range. you remain in end this will more to track the this year. efforts on comfortably We shared require this Our targeting year, by XXX market that land
driving hospital driver building is second Our growth awareness existing at customers. adoption deeper and
our target continue are and these for Education alone. treated anticoagulation of for As high decisions currently you physicians to and with we treatment populations non-interventional percentage responsible a important DVT and is often engage are patient effectively. patients physicians know, these of training PE who the
Program We patients. as patients establish execute centers continue providing are are rates like to program. positions to those are VTE climbing. is processes heart have We which efforts to these to and also designated results. we More VTE yielding the consistently and VTE updates systematic forward stroke example, and targeted administrators Excellence quarter are to our Altogether, identify experts. triage adopted The for establish systems the to VTE attack for goal penetration working coordinator centers, every look establishing we encouraging with
a in treated with results anticoagulation ever reviewed the ICU all remains to best-in-class treatment better data six with disease on The survivors in of now days. months, recently safety represent FlowTriever patient the recording stay of journal, as disease, orders thrombectomy a FlowTriever reduction and separate up, field reported and PE. treated literature impressive system, confirm an showed our with this improvement, ICU Our at of while are as zero fundamentally prospective treated FLASH of all consequences We Perhaps lot conservative follow a profile FlowTriever Patients that points natural course patients mortality cause out In patients changes patients the of a well this mortality enrolled we four-day believe study the This driver are than of colleagues share analytics. high upon study comparison Registry the in-hospital week. dataset clinical management. CTED, The at PE were already of XXX build reduction ever third last the terrible Buckley interventional this the magnitude again first impressive. as into impact patients the in which represents have of with base device medical Dr. to TCT evidence. the from and Data are PE with presented topic. first for rates reported Conference for largest a growth stay. treated FlowTriever to clinical our on data median published the of those in is XX% the CTEST exciting, peer long-term we to more table the
we Finally, remains Site pleased randomized comparing underway. we catheter-directed control enrollments XXXX. report is on peerless expect schedule. patient protocol are QX to selection is of in And our first thrombolysis trial The to that FlowTriever complete.
fourth Our our expand is exciting well. driver here product developments growth to as portfolio,
to has FlowSaver expectations. First, up lived
physician increased and many has patient FlowTriever future has during loss. This a bloodless times down is Bloodless to fact has the high is blood X,XXX because concern highly reminder, the per whoosh to bar XX%. FlowSaver without loss brisk. it important necessary for been allowing the thrombectomy. blood been even As a is in FlowSaver XX%, both thrombectomy for blood and aspirated return to as procedure as patients, a in is virtually per simply number Adoption procedure used Estimated device and set existing as physicians procedures. nearly valuable procedure by the for it’s performance of whooshes already used competitors. enables by
system, which and DVT. Bold The for more more in clot aggressive October. Next, us allow clots we the treat may received ClotTriever FDA older is Bold clearance advanced reverse a to
States will time a all first a about bring to ulcers. develops to In products There that product with are We’ll patients PTS to along progressive fact, remainder leg post-thrombotic of with half cause and horrendous say over in about in we the or in at venous and in treat results XX% right DVT quarters. leg of patients suite least now of our PTS. is ulcers syndrome market the with condition United have the more X patients PTS million the of often about them. represents robust is venous Bold ClotTriever of pipeline untreated it coming over the
The and we and into Europe continue expansion fifth final operating launching make business. has on Our and international to adjacent progress markets. environment across growth stabilized driver is this
combination direct across a European feedback we physicians from are and all commercial in remain team markets our highly and a of seeing increases Enthusiasm case partnerships. through established monthly volumes. successfully positive We have steady and major distribution third-party presence
supporting driving help executing longer also In clarity term out initial our need on franchise. build we will cases, addition European strategies gaining to are to we and and reimbursement and clinical
paths We remain not in for timelines on years we believe longer the regulatory optimistic very both contribute about and although the remain approval the will that immediate Europe, making Japan in potential but we’re term. Beyond away. term business, progress materially international China,
opportunity Finally, business. our is the I important just close work appreciate than reminding always us me to that more here to by
continued and with We support. appreciate you a along possibilities are extraordinary committed appreciate in your mission. we to We believing us
to turn just We started. We to and can believe With many we I’d grow like and to years sustainably aggressively will for over come. getting that, are things Mitch.
